Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628027 | 0.85 | TACR1 (0.47) | IDO1MPOTPOCYP3A4TACR1 | |
| SCHEMBL2633216 | 0.78 | SLC7A5 (0.40) | IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL2628022 | 0.77 | CNR2 (0.39) | IDO1TDO2MPOTPOCYP3A4 | |
| SCHEMBL11077274 | 0.75 | IDO1 (0.52) | IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL7538162 | 0.73 | SLC6A2 (0.43) | IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL2628025 | 0.73 | SLC6A2 (0.43) | IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL3580534 | 0.73 | TSHR (0.50) | IDO1MPOTPOCYP3A4AGXT | |
| SCHEMBL7964372 | 0.73 | TSHR (0.50) | IDO1MPOTPOCYP3A4AGXT | |
| SCHEMBL22785928 | 0.71 | CA1 (0.47) | IDO1TDO2CYP3A4SLC6A9SLC6A5 | |
| SCHEMBL28549454 | 0.71 | CHRM3 (0.44) | IDO1SLC6A4AGXTCNR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | IDO1 631/4885TDO2 4219/4885MPO 4570/4885 |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | IDO1 631/4885TDO2 4219/4885MPO 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.